Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 6. Immunological characteristics of TERTp-mutant gliomas in TCGA. (A, B) Expression matrices showing proportions and expression patterns of 22 tumor-infiltrating immune cell types in TCGA-glioma tissues from patients with TERTp mutations in the high- and low-risk groups. (C) Profiling of tumor-infiltrating immune cells in TERTp-mutations-type glioma tissues in the high- and low-risk groups in TCGA. (D) Predicted proportions of ICB responders and non-responders among glioma patients with TERTp mutations in the high-risk and low-risk groups.